Recruiting

Exercise Training

Sponsor:

McGill University

Code:

NCT05646407

Conditions

Chronic Obstructive Pulmonary Disease

Interstitial Lung Disease

Heart Failure

Eligibility Criteria

Sex: All

Age: 40+

Healthy Volunteers: Not accepted

Interventions

Honeywell HT-900 Turbo Force Air Circulator

Study Details

Brief summary:

The purpose of this study is to explore the role of a stream of cool air to the face, through fan-to-face therapy, as a novel adjunct non-pharmacological therapy to enable symptomatic adults with cardiopulmonary disease to exercise at higher intensities for longer durations and maximize the psycho-physiological benefits of a supervised exercise training program. The investigators hypothesize that, compared to no fan, fan-to-face therapy will result in relatively greater improvements in exercise endurance time and intensity ratings of perceived breathlessness during constant-load cardiopulmonary exercise testing on a treadmill at 75% of peak power output following a 5-week exercise training period.

Conditions

Chronic Obstructive Pulmonary Disease

Interstitial Lung Disease

Heart Failure

Study ID

NCT05646407

Start date

Apr 1, 2023

Status verified date

Feb, 2024

Completion date

Mar 30, 2025

Anticipated

Primary completion date

Dec 31, 2024

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 40+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • have a physician diagnosis of cardiopulmonary disease (e.g., chronic obstructive pulmonary disease, interstitial lung disease, heart failure)
  • have a body mass index of >18.5 kg/m2 and <35 kg/m2
  • be cleared to participate in a supervised exercise training program by their primary care physician

Exclusion Criteria:

  • have changed their respiratory or cardiac medication dosage and/or frequency of administration in preceding two weeks
  • have had a disease exacerbation/hospitalization in preceding six weeks
  • have important contraindication(s) to exercise (e.g., significant musculoskeletal or neurological disease) or pulmonary function testing (e.g., eye, chest or stomach surgery, or any history of coughing up significant amounts of blood in the previous 3 months).

Study Design

Enrollment

32 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: Exercise training with Fan-to-face

Participants randomized to the fan-to-face group will perform supervised exercise training with a basic, portable fan (Honeywell HT-900 Turbo Force Air Circulator). The fan will be placed to the front of the treadmill with airflow directed toward the area of the face innervated by the second and third branches of the trigeminal nerve. The airflow speed will be chosen by each participant so that it is most comfortable to them. An anemometer will measure the airflow from the fan.

no intervention: Exercise training with no fan

Participants randomized to the no fan group will perform supervised exercise training with no fan. The exercise duration and intensity titration will follow the same format as the experimental group.

Interventions

Honeywell HT-900 Turbo Force Air Circulator

This is a basic, portable, household fan with a single cost of CDN$21.99.

Primary outcome measure

  • Cardiopulmonary exercise testing endurance time [ Time Frame: Pre- and post-5 week of exercise training period. ]
  • Borg modified 0-10 category ratio scale for breathlessness intensity [ Time Frame: Pre- and post-5 week of exercise training period. ]

Central Contacts and Locations

Central contacts

Locations

Centre of Innovative Medicine of the McGill University Health Centre

Recruiting

Montreal, Quebec, Canada, H4A 3J1

Contacts

More Information

Sponsor

McGill University

Last update posted

Feb 15, 2024

Last verified

Feb, 2024

Keywords

  • Breathlessness
  • Dyspnea
  • Exercise
  • Fan-to-face therapy
  • Cool air
  • Exercise intolerance

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by McGill University on 2024-02-15.